First EMA Nod For Generic Xarelto; Apotex Pulls Upkanz For Neurodegenerative Disease

While Accord HealthCare has convinced the European Medicines Agency that its rivaroxaban generic should be approved in the EU, Bayer has warned that patent protection for Xarelto continues until at least late 2023. The EMA this week also recommend approval for a number of other new drugs.

ApproveOnKeyboard_1200x675
The EMA has recommended that a number of new drugs be approved • Source: Shutterstock

The European Medicines Agency this week recommend that seven new drugs be awarded pan-EU marketing approval, including Rivaroxaban Accord (rivaroxaban), which appears to be the first generic version of Bayer’s blockbuster anticoagulant Xarelto to go through the agency’s centralized approval pathway. 

Also recommended for approval were two vaccines from Sanofi – MenQuadfi, for prophylaxis against invasive meningococcal disease, and Supemtek...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet